IVT mRNA Production

By utilizing in vitro transcribed (IVT) messenger RNA (mRNA) molecules, scientists can deliver specific instructions to cells, directing them to produce therapeutic proteins or trigger desired immune responses.

GenScript utilizes advanced gene synthesis platforms along with plasmid preparation and linearization services to produce best in class IVT templates. Building on that expertise, GenScript has created an integrated manufacturing workflow that spans from codon-optimized genes to mRNA Production to Lipid Nanoparticle (LNP) delivery.

Dowload this eBook to find out how to:

• Achieve superior quality in IVT mRNA
• Drive new therapy modalities
• Enhance protein expression with circular RNA
• Deliver your therapeutics efficiently and safely
• Optimize the performance of your therapeutics

Delve into exciting new technologies pushing the boundaries in research and advancing the development of novel therapeutics. Through a series of engaging presentations by experts in the fields of synthetic peptide technologies, genome editing, and drug development, our speakers will dive into the latest advances and trends in neoantigen peptide discovery for personalized cancer immunotherapy, the promising potential of mRNA-based tools for gene editing, and the innovative world of self-amplifying RNAs as a cutting-edge modality, shaping the next generation of RNA vaccines.

The remarkable success of SARS-CoV2 vaccines has brought to light the incredible potential of in vitro transcribed RNA as a ground-breaking vaccine platform. Unlike traditional vaccines, RNA vaccines offer the exciting possibility of swift development and production, enabling rapid responses to emerging diseases. A recent breakthrough in RNA vaccine technology is the development of self-amplifying RNAs, which not only generate higher levels of immunogens but also require lower doses compared with conventional RNA vaccines.

This webinar will delve into the innovative world of self-amplifying RNAs as a cutting-edge RNA modality. Throughout the session, we will explore what self-amplifying RNAs are, how they differ from conventional RNA and their potential impact on shaping the next generation of RNA vaccines and other therapeutic applications.

Join Mark Shulewitz, PhD, senior scientist at GenScript for an enlightening discussion on the future of vaccine technology.

Key learning objectives

• Learn how RNA is used in vaccines and other therapeutic applications such as protein replacement therapy
• Discover what modalities of RNA are currently being explored for therapeutic applications
• Explore the shortcomings of conventional RNA and how self-amplifying RNA addresses some of these issues
• Gain insight into the latest developments in self-amplifying RNAs

Who should attend?

• Experienced RNA users interested in learning more about self-amplifying RNA
• Absolute beginners interested in learning about self-amplifying RNA
• Researchers interested in RNA vaccine development and protein replacement therapies
• Life science, biopharma and pharmaceutical professionals interested in cutting-edge technologies that have multiple applications in therapeutic development and basic life science research
• Developers of traditional vaccines looking for a new approach

Interested in this webinar? Explore the other webinars in this series on Applications and Challenges of Neoantigen Peptides in Personalized Cancer Vaccines and Advanced mRNA and LNP Strategies for CRISPR Delivery

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes